Eumentis Therapeutics

About:

Eumentis is a biopharmaceutical company developing treatments for neuropsychiatric conditions.

Top Investors: U.S. Department of Defense, Joyance Partners, Small Business Innovation Research, Social Starts, Life Science Angels

Description:

Eumentis is a biopharmaceutical company developing treatments for neuropsychiatric conditions. Its product candidate EM-221 is an oral PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum.

Total Funding Amount:

$8.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2019-01-01

Founders:

Stuart Lipton

Number of Employees:

11-50

Last Funding Date:

2023-02-08

IPO Status:

Private

Industries: